Hospital General Universitario Morales Meseguer — Clinical Trial Site

99 Registered trials

40 Currently recruiting

Organisation

Hospital General Universitario Morales Meseguer

Location

Murcia, Spain

Identifier

ORG-100028583

Address

Avenida Del Marques De Los Velez S/n, 30008, Spain

Departments

-
#2601 Hematología
#3854: Hematología
1322: Hematología
3403: Hematology
7010: Oncología
724005; Hematology
ES10003: Hematología
General and Digestive Surgery
general surgery and digestive system
Hematolgy
Hematología
Hematology
Hematology and Hemotherapy
Hematology and Medical Oncology
Hematology and Medical Oncology Service
Hematology Department
Hematology Service
Hematology Unit
Hematology/ Oncology
Infectious Diseases
Internal Medicine
Internal medicine- Infectious Disease Department
Medical Oncology
Medical oncology service.
Oncología
Oncología Médica
Oncology
Oncology Service
Servicio de Hematología
Servicio de Hematología y Oncología Médica
Servicio de Oncologia
Servicio de Oncología Médica
Surgery
Urología
Urology

Clinical trials at this site (99)

Search interface

Pacritinib for Patients With Myelofibrosis Who Have Thrombocytopenia Recruiting

2025-522509-39-00 Patients with myelofibrosis and platelets counts betwee 4 2026-03-30
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2026-03-12
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Neuroendocrine tumors 10 2026-01-27
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient… Recruiting

2024-515511-21-00 Neuroendocrine Carcinoma / G3 Neuroendocrine Tumours 4 2025-03-13
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an… Recruiting

2024-512900-20-00 Non-muscle invasive bladder cancer (NMIBC) 7 2025-01-30
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat… Recruiting

2024-512835-53-00 Diffuse Large B-Cell Lymphoma 4 2024-11-20
Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting

2024-516011-24-01 Cytomegalovirus infection in allogeneic stem cell trans 4 2024-11-13
A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting

2023-505242-25-00 High-Risk Monoclonal Gammopathy of Undetermined Signifi 4 2024-11-05
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjug… Recruiting

2023-504898-20-00 Thyroid neoplasms: ● Cohort 1: Advanced radioactive-iod 4 2024-07-30
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting

2024-511959-18-01 Acute Pulmonary Embolism 5 2024-07-01
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting

2023-505621-13-00 Richter´syndrome 4 2024-05-14
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Mantle Cell Lymphoma (MCL) 5 2023-11-20
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop… Recruiting

2022-501831-18-00 Patients with hematologic malignancies and undergoing a 4 2023-09-13
A Study in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment with Pozelimab + Cemdisira… Recruiting

2023-510336-36-00 Paroxysmal nocturnal hemoglobinuria (PNH) 5 2023-05-05
HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF) Recruiting

2023-504943-15-00 Cancer(colon cancer stage II-III, rectal cancer, and br 4 2022-08-19
FI-3, Fidelia Recruiting

2024-518243-38-00 Fecal incontinence in female and male patients 5 2022-04-20
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19